Previous studies have demonstrated that recurrent mutations in genes involved in epigenetic regulation, such as TET2 and ASXL1, are present in more than half of BPDCN cases [2, 19–23]. Here, ASXL1 is linked to CD4+/CD56+ hematodermic neoplasm.